Physician profile
John Benjamin Groves
NPI 1801202312
$3,084.47
in general payments reported to CMS, 2019-2025
32 companies · $815 in 2025
The $815 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.05 · 2021: $454 · 2022: $642 · 2023: $353 · 2024: $792 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.76 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.74 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $304.33 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $242.14 | 2022-2025 | Veozah |
| Novo Nordisk INC | $174.89 | 2021-2025 | Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $166.82 | 2022-2025 | |
| Abbott Laboratories | $160.01 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $128.89 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $121.15 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Lilly USA, LLC | $115.54 | 2021-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $105.41 | 2024-2025 | Auvelity |
| Dexcom, INC. | $91.91 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $70.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.16 | 2021-2022 | |
| Gilead Sciences, INC. | $66.78 | 2023-2025 | |
| Esperion Therapeutics, INC. | $64.21 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.83 | 2022-2024 | Evenity, Prolia |
| Mannkind Corporation | $59.40 | 2022 | |
| Exact Sciences Corporation | $53.97 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $51.01 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Kestra Medical Technology Services, INC. | $46.73 | 2025 | Assure Wcd |
| Amarin Pharma, INC. | $31.26 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.48 | 2025 | Fanapt |
| Sanofi-Aventis U.S. LLC | $27.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.38 | 2022 | |
| Smith+Nephew, INC. | $25.37 | 2022 | |
| Daiichi Sankyo INC. | $22.30 | 2023 | Injectafer |
| Sunovion Pharmaceuticals INC. | $19.50 | 2022 | |
| Lundbeck LLC | $18.47 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $17.56 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.32 | 2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $15.49 | 2021 | |
| Eisai INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Groves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.